IDT Biologika

Photo
01.07.2024 • News

SK Bioscience Acquires Majority Stake in IDT Biologika

South Korea-headquartered contract development and manufacturing organization (CDMO) SK Bioscience plans to acquire a 60% stake in IDT Biologika, a German CDMO specialized in vaccines, gene and immune therapy and oncolytic viruses, from Klocke Group. Klocke will retain a 40% stake in IDT Biologika and thus remains the company's second-largest shareholder.

Photo
04.03.2022 • News

IDT Biologika and Exothera Join on Vaccine Scale-up

IDT Biologika, a German CDMO specialized in vaccines, gene and immune therapy and oncolytic viruses, is collaborating with Belgian CDMO Exothera on developing a large-scale manufacturing process for viral vector-based vaccines. The two firms are currently conducting a feasibility study focused on the Modified Vaccinia Ankara (MVA) virus as a first project to come out of IDT’s broad range of vector technologies.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.